Analysts from Cantor Fitzgerald have rated AmSurg stock at “buy,” according to an Analyst Ratings report.
Cantor Fitzgerald set the company’s shares at a price target of $67. AmSurg has a market cap of $2.98 billion.
More articles on transactions and valuation issues:
How much does it cost to build an outpatient surgery center?
SCA closes secondary public offering of common stock
AmSurg acquires Halifax Anesthesiology Associates
Tonya Becker, RN, a former employee of recently shuttered Sturm Cosmetic Surgery in Ames, Iowa, has filed a lawsuit against…
In November 2024, President Donald Trump chose Mehmet Oz, MD, as his nominee to lead CMS. Nomination hearings for the…
Medicare payments to ASCs jumped nearly $2 billion between 2018 and 2023, according to a March 13 MedPAC report to…
